Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)

NCT ID: NCT00817245

Last Updated: 2009-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Etiology of ICSCR is not known however recent studies regard the role of immunologic and infectious processes in the pathogenesis of ICSCR.one of these hypothesis is the role of helicobacter pylori in the pathogenesis of ICSCR so perhaps treatment of h pylori have positive effect on the remission of ICSCR.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

we will choose 50 cases of patients with ICSCR who are infected with h.pylori.25 cases will receive anti h.pylori regiment and 25 cases as controls will receive no medication.then we will compare the time of submacular fluid resorption and macular thickness and visual acuity among these two groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Serous Chorioretinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule

Group Type ACTIVE_COMPARATOR

omeprazole, Amoxicillin, metronidazole

Intervention Type DRUG

we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR

2

No medical treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

omeprazole, Amoxicillin, metronidazole

we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

treatment of Central serous chorioretinopathy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* the persons who are infected with helicobacter pylori and have ICSCR

Exclusion Criteria

* history of previous eye surgery ,to have indication of laser therapy,corticosteroid therapy,pregnancy,
Minimum Eligible Age

28 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tabriz University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tabriz University of Medical Sciences

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alireza Javadzadeh

Role: STUDY_CHAIR

Alireza Javadzadeh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alireza JavadzadehTabriz

Tabriz, , Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

References

Explore related publications, articles, or registry entries linked to this study.

Lange CA, Qureshi R, Pauleikhoff L. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.

Reference Type DERIVED
PMID: 40522203 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

86-47

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.